influenza
virus
iav
circul
waterfowl
natur
reservoir
categor
base
antigen
properti
hemagglutinin
ha
neuraminidas
na
protein
differ
nine
differ
na
present
wild
frequent
wild
bird
infect
poultri
result
cull
million
bird
signific
econom
loss
howev
wild
bird
rare
show
diseas
symptom
iav
poultri
usual
exhibit
respiratori
tropism
abl
mutat
highli
pathogen
influenza
also
zoonot
diseas
viru
occasion
transmit
infect
poultri
human
certain
hana
combin
howev
seem
favor
human
infect
caus
sever
devast
outbreak
human
past
spanish
flu
asian
pandem
hong
kong
pandem
swine
flu
current
recent
emerg
strain
concern
global
public
health
avian
influenza
lpai
first
discov
human
china
three
patient
hospit
sever
fatal
sinc
six
epidem
wave
result
human
infect
death
seventh
wave
current
intriguingli
viru
isol
outbreak
suggest
deriv
chicken
show
mild
symptom
diseas
investig
reveal
viral
gene
exclus
avian
date
report
human
human
transmiss
even
though
exclud
case
howev
case
human
infect
attribut
exposur
human
infect
wild
bird
poultri
live
anim
crucial
step
life
cycl
influenza
subtyp
cleavag
ha
fusion
protein
host
proteas
ha
synthes
precursor
requir
proteolyt
process
exert
fusogen
activ
cleavag
occur
fusion
peptid
result
exposur
allow
ha
induc
fusion
viral
cellular
membran
subsequ
releas
rna
host
lpai
virus
monobas
cleavag
site
consist
singl
arginin
preced
three
amino
acid
influenza
lpai
virus
wild
bird
usual
cleav
trypsin
tract
serin
proteas
human
poultri
resid
respiratori
tract
abl
process
virus
therefor
diseas
usual
confin
littl
known
activ
virus
previous
report
type
ii
transmembran
serin
proteas
play
role
cleavag
ha
activ
viru
studi
show
knockout
ko
mice
highli
toler
infect
ko
mice
complement
human
mous
suscept
viru
recent
report
human
matriptasest
abl
effici
cleav
cleavag
motif
peptid
matriptasest
proteas
local
epitheli
cell
variou
tissu
human
seem
play
signific
role
activ
variou
influenza
subtyp
howev
result
obtain
use
cleavag
site
peptid
mimic
alway
reflect
vivo
situat
need
show
human
matriptasest
cleav
ha
result
fusogen
activ
protein
demonstr
matriptasest
promot
infect
pseudoparticl
carri
ultim
provid
data
show
activ
viru
human
matriptasest
lead
high
infect
cell
cultur
togeth
data
suggest
matriptasest
novel
proteas
human
respiratori
tract
promot
infect
vero
mdck
cell
american
type
cultur
collect
use
influenza
experi
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
mm
hepe
cellgro
hyclon
fetalclon
ii
ge
human
isol
influenza
viru
gift
stacey
st
jude
children
hospit
memphi
tn
usa
viru
propag
cell
cultur
brief
flask
confluent
mdck
cell
inocul
differ
dilut
cell
monitor
daili
cytopathogen
effect
supernat
harvest
cellsflask
dead
supernat
combin
viral
titer
quantifi
describ
pdz
plasmid
encod
ha
na
kindli
provid
dr
adolfo
icahn
school
medicin
mount
sinai
new
york
citi
ny
usa
murin
leukemia
viru
mlv
packag
construct
transfer
vector
encod
luciferas
report
plasmid
describ
recombin
human
matriptasest
purchas
r
system
specif
activ
enzym
describ
fluorogen
peptid
substrat
cell
grown
plate
transfect
ha
na
use
turbofect
accord
manufactur
recommend
invitrogen
eighteen
hour
cell
wash
pb
nm
matriptasest
matriptas
buffer
mm
tri
mm
mm
nacl
ph
ad
one
well
incub
rocker
minut
control
mm
trypsin
pb
ad
minut
cell
process
western
blot
analysi
previous
antibodi
detect
ha
obtain
biodefens
emerg
infect
research
resourc
repositori
secondari
antibodi
alexa
fluor
tag
purchas
invitrogen
western
blot
membran
scan
use
chemidoc
imag
system
facilit
exposur
linear
rang
band
quantifi
use
imagej
softwar
cleavag
effici
calcul
follow
equat
graph
gener
use
graphpad
prism
softwar
vero
cell
grown
plate
contain
glass
cover
slide
transfect
ha
na
use
lipofectamin
accord
manufactur
recommend
invitrogen
eighteen
hour
cell
wash
nm
matriptasest
matriptas
buffer
ad
incub
rocker
hour
control
cell
incub
nm
trypsin
pb
minut
fusion
immunofluoresc
assay
perform
previous
pseudoparticl
product
cell
grown
plate
transfect
ha
na
use
turbofect
accord
manufactur
recommend
control
transfect
posit
control
neg
control
supernat
harvest
hour
pseudoparticl
store
infect
cell
lysi
data
analysi
perform
previous
experi
repeat
three
independ
time
result
plot
statist
analysi
conduct
use
graphpad
softwar
experi
viru
conduct
biosafeti
level
condit
mdck
cell
grown
plate
confluenc
moi
incub
nm
matriptasest
matriptas
buffer
nm
trypsin
flu
infect
medium
dmem
nm
hepe
bsa
minut
neg
control
viru
incub
flu
infect
medium
minut
control
matriptasest
viru
ad
one
well
mdck
cell
incub
rocker
minut
minut
flu
infect
medium
ad
cell
grown
viru
hour
hour
supernat
collect
store
viral
titer
analyz
use
assay
previous
experi
repeat
three
independ
time
data
statist
analysi
perform
use
graphpad
softwar
previous
report
recombin
human
matriptasest
cleav
fluorogen
peptid
mimick
cleavag
site
motif
ha
unlik
situat
proteas
test
result
vmax
valu
matriptasest
significantli
differ
trypsin
serv
posit
control
howev
result
obtain
peptid
assay
use
ha
cleavag
site
mimic
alway
translat
observ
made
therefor
express
ha
cell
subsequ
ad
recombin
human
matriptasest
minut
proteas
ad
neg
control
incub
trypsin
serv
posit
control
observ
cleavag
ha
without
proteas
effici
cleavag
trypsin
ad
figur
recombin
human
matriptasest
cleav
lesser
extent
trypsin
figur
quantif
reveal
trypsin
convert
matriptasest
proteolyt
process
figur
next
interest
see
whether
matriptasest
cleavag
ha
result
fusogen
activ
protein
therefor
express
ha
vero
cell
incub
cell
subsequ
recombin
human
matriptasest
three
hour
control
describ
neg
control
without
ad
proteas
show
cell
fusion
figur
howev
trypsin
matriptasest
ad
cell
express
ha
strong
syncytia
format
observ
figur
conclus
recombin
human
matriptasest
proteolyt
process
ha
abl
exert
fusogen
activ
establish
recombin
human
matriptasest
cleavag
result
fusogen
ha
protein
want
test
whether
would
promot
infect
viru
first
step
chose
produc
pseudoparticl
repres
surrog
nativ
virion
allow
us
studi
viral
entri
host
cell
pseudoparticl
use
assay
possess
mlv
core
incorpor
luciferas
report
gene
upon
releas
produc
facilit
fusion
pseudovirion
contain
ha
incub
trypsin
matriptasest
prior
addit
cell
use
two
neg
control
pseudoparticl
ha
proteas
treatment
b
pseudoparticl
without
fusion
protein
addit
control
infect
gener
pseudoparticl
use
pseudovirion
carri
fusion
protein
requir
proteolyt
cleavag
cell
lyse
hour
infect
pseudoparticl
cell
lysat
mix
luciferas
substrat
measur
rel
fluoresc
provid
quantit
analysi
infect
pseudoparticl
carri
highli
infect
show
pseudoparticl
product
work
expect
figur
tabl
ha
pseudovirion
treat
trypsin
matriptasest
significantli
infecti
compar
pseudoparticl
without
proteas
treatment
figur
tabl
howev
signific
differ
matriptasest
pseudoparticl
suggest
pseudovirion
deplet
figur
tabl
pseudoparticl
without
incorpor
fusion
protein
infecti
data
show
matriptasest
cleavag
ha
result
fulli
infecti
virion
abl
fuse
host
cell
next
investig
whether
matriptasest
abl
sustain
promot
viral
growth
cell
cultur
system
therefor
infect
mdck
cell
live
viru
low
moi
ad
trypsin
matriptasest
control
receiv
proteas
treatment
hour
supernat
collect
viral
titer
quantifi
use
assay
influenza
treat
proteas
exhibit
titer
pfuml
figur
tabl
viru
treat
trypsin
matriptasest
howev
significantli
higher
titer
approxim
pfuml
respect
figur
tabl
togeth
data
suggest
human
matriptasest
cleav
ha
may
significantli
contribut
viral
growth
influenza
human
influenza
virus
caus
signific
number
causal
sinc
emerg
pose
major
threat
public
health
abil
continu
evolv
find
virus
wave
antigen
distinct
virus
emerg
render
exist
candid
vaccin
novel
approach
fight
influenza
infect
includ
target
host
proteas
respons
activ
major
benefit
approach
unlik
lead
resist
phenotyp
viru
howev
requir
inform
proteas
distinct
influenza
ha
subtyp
proteolyt
activ
far
type
ii
transmembran
serin
proteas
human
proteas
associ
activ
lpai
ko
mice
show
clinic
sign
diseas
limit
spread
viru
infect
howev
mice
still
exhibit
low
titer
viru
sever
day
suggest
proteas
abl
cleav
lpai
ha
data
strongli
suggest
matriptasest
major
role
cleav
lpai
fact
ko
mice
show
clinic
sign
diseas
may
translat
human
infect
sinc
evid
sole
enzym
respons
spread
viru
human
matriptasest
identifi
one
import
host
proteas
cleav
ha
directli
manner
indirectli
activ
date
report
demonstr
matriptasest
cleavag
ha
matriptasest
also
express
select
ha
cleavag
particular
strain
within
context
work
import
point
vast
major
human
lpai
strain
share
ha
cleavag
site
motif
analyz
lpai
sequenc
human
isol
collect
avail
gisaid
databas
http
seven
sequenc
show
chang
ha
cleavag
site
motif
six
strain
exhibit
k
r
substitut
posit
one
strain
k
q
chang
posit
data
shown
emphas
requir
viru
activ
larg
remain
even
though
antigen
differ
strain
evolv
past
year
howev
data
predict
matriptasest
would
abl
proteolyt
process
chang
cleavag
site
recent
show
matriptasest
cleav
peptid
repres
lpai
ha
cleavag
motif
effici
use
assay
fluorogen
peptid
repres
differ
ha
subtyp
cleavag
site
mimic
limit
assay
peptid
may
produc
result
structur
interact
proteas
cleavag
site
might
alter
compar
ha
protein
matriptasest
exampl
report
proteolyt
process
ha
cleavag
site
motif
peptid
matriptasest
test
ha
protein
express
cell
littl
cleavag
produc
fusogen
ha
cleavag
observ
demonstr
human
matriptasest
cleav
ha
express
cell
result
fulli
fusogen
activ
protein
valid
result
previous
publish
peptid
assay
matriptasest
cleavag
ha
also
promot
infect
pseudovirion
viru
cell
cultur
data
indic
human
matriptasest
relev
proteas
caus
lpai
infect
human
may
repres
import
pathogen
determin
target
therapeut
intervent
